Steady state kinetics of pyridostigmine in myasthenia gravis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Steady state kinetics of pyridostigmine in myasthenia gravis. / Sørensen, P S; Flachs, H; Friis, M L; Hvidberg, E F; Paulson, O B.

I: Neurology, Bind 34, Nr. 8, 08.1984, s. 1020-4.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sørensen, PS, Flachs, H, Friis, ML, Hvidberg, EF & Paulson, OB 1984, 'Steady state kinetics of pyridostigmine in myasthenia gravis', Neurology, bind 34, nr. 8, s. 1020-4. https://doi.org/10.1212/wnl.34.8.1020

APA

Sørensen, P. S., Flachs, H., Friis, M. L., Hvidberg, E. F., & Paulson, O. B. (1984). Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology, 34(8), 1020-4. https://doi.org/10.1212/wnl.34.8.1020

Vancouver

Sørensen PS, Flachs H, Friis ML, Hvidberg EF, Paulson OB. Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology. 1984 aug.;34(8):1020-4. https://doi.org/10.1212/wnl.34.8.1020

Author

Sørensen, P S ; Flachs, H ; Friis, M L ; Hvidberg, E F ; Paulson, O B. / Steady state kinetics of pyridostigmine in myasthenia gravis. I: Neurology. 1984 ; Bind 34, Nr. 8. s. 1020-4.

Bibtex

@article{106ea65addb24b199b1b3e158143898f,
title = "Steady state kinetics of pyridostigmine in myasthenia gravis",
abstract = "We measured the fluctuations in plasma pyridostigmine concentration from day to day on 3 consecutive days and hour to hour during 1 day in 11 myasthenic patients, by studying their usual dosage regime. Plasma pyridostigmine was measured by gas chromatography/mass spectrometry. The intraindividual day-to-day variation in plasma pyridostigmine levels was small. A highly significant relationship was found between the oral pyridostigmine dose and the area under the plasma concentration/time curve. The bioavailability of oral pyridostigmine was 3.6%, estimated by replacing one dose with an intravenous dose amounting to 1/30 of the oral dose. The relatively stable kinetic behavior of pyridostigmine is in contrast to the interpatient variability in dose requirement, indicating that monitoring of plasma pyridostigmine levels should be reserved for special cases.",
keywords = "Administration, Oral, Adult, Biological Availability, Female, Humans, Kinetics, Male, Middle Aged, Myasthenia Gravis/drug therapy, Pyridostigmine Bromide/administration & dosage",
author = "S{\o}rensen, {P S} and H Flachs and Friis, {M L} and Hvidberg, {E F} and Paulson, {O B}",
year = "1984",
month = aug,
doi = "10.1212/wnl.34.8.1020",
language = "English",
volume = "34",
pages = "1020--4",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "8",

}

RIS

TY - JOUR

T1 - Steady state kinetics of pyridostigmine in myasthenia gravis

AU - Sørensen, P S

AU - Flachs, H

AU - Friis, M L

AU - Hvidberg, E F

AU - Paulson, O B

PY - 1984/8

Y1 - 1984/8

N2 - We measured the fluctuations in plasma pyridostigmine concentration from day to day on 3 consecutive days and hour to hour during 1 day in 11 myasthenic patients, by studying their usual dosage regime. Plasma pyridostigmine was measured by gas chromatography/mass spectrometry. The intraindividual day-to-day variation in plasma pyridostigmine levels was small. A highly significant relationship was found between the oral pyridostigmine dose and the area under the plasma concentration/time curve. The bioavailability of oral pyridostigmine was 3.6%, estimated by replacing one dose with an intravenous dose amounting to 1/30 of the oral dose. The relatively stable kinetic behavior of pyridostigmine is in contrast to the interpatient variability in dose requirement, indicating that monitoring of plasma pyridostigmine levels should be reserved for special cases.

AB - We measured the fluctuations in plasma pyridostigmine concentration from day to day on 3 consecutive days and hour to hour during 1 day in 11 myasthenic patients, by studying their usual dosage regime. Plasma pyridostigmine was measured by gas chromatography/mass spectrometry. The intraindividual day-to-day variation in plasma pyridostigmine levels was small. A highly significant relationship was found between the oral pyridostigmine dose and the area under the plasma concentration/time curve. The bioavailability of oral pyridostigmine was 3.6%, estimated by replacing one dose with an intravenous dose amounting to 1/30 of the oral dose. The relatively stable kinetic behavior of pyridostigmine is in contrast to the interpatient variability in dose requirement, indicating that monitoring of plasma pyridostigmine levels should be reserved for special cases.

KW - Administration, Oral

KW - Adult

KW - Biological Availability

KW - Female

KW - Humans

KW - Kinetics

KW - Male

KW - Middle Aged

KW - Myasthenia Gravis/drug therapy

KW - Pyridostigmine Bromide/administration & dosage

U2 - 10.1212/wnl.34.8.1020

DO - 10.1212/wnl.34.8.1020

M3 - Journal article

C2 - 6540381

VL - 34

SP - 1020

EP - 1024

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -

ID: 279594917